Jon Jyoti Sahariah | Medicinal Chemistry | Research Excellence Award

Research Excellence Award

Jon Jyoti Sahariah
Dibrugarh University, India

Jon Jyoti Sahariah
Affiliation Dibrugarh University
Country India
Scopus ID 57225212218
Documents 19
Citations 125
h-index 6
Subject Area Medicinal Chemistry
Event Indian Scientist Awards

Jon Jyoti Sahariah is an academic researcher affiliated with Dibrugarh University, India, whose scholarly activities are associated with medicinal chemistry, pharmaceutical sciences, drug delivery systems, and therapeutic development. His published research contributions demonstrate engagement with contemporary challenges in drug discovery, targeted therapeutics, and biomedical innovation. Through peer-reviewed publications, citation impact, and interdisciplinary collaborations, he has contributed to advancing scientific understanding within medicinal chemistry and related biomedical disciplines.[1]

Abstract

This article presents an academic overview of Jon Jyoti Sahariah and his scholarly contributions within medicinal chemistry and pharmaceutical research. The profile summarizes research interests, publication records, citation metrics, scientific influence, and relevance to recognition through the Research Excellence Award. The assessment is based on publicly available scholarly indicators and peer-reviewed academic outputs.[1]

Keywords

Medicinal Chemistry, Drug Discovery, Pharmaceutical Sciences, Targeted Drug Delivery, Cancer Therapeutics, Liposomal Formulations, Biomedical Research, Therapeutic Development, Scientific Publications, Research Excellence.

Introduction

Medicinal chemistry plays a critical role in the development of novel therapeutic agents and advanced healthcare solutions. Researchers working in this field contribute to the identification, optimization, and evaluation of biologically active compounds for the prevention and treatment of diseases. Jon Jyoti Sahariah’s academic activities align with these objectives through investigations focused on pharmaceutical formulations, drug delivery systems, and therapeutic innovations. His work reflects interdisciplinary collaboration across chemistry, pharmacy, and biomedical sciences.[2]

Research Profile

The scholarly profile of Jon Jyoti Sahariah demonstrates sustained participation in scientific research and publication. According to available bibliometric indicators, his research output includes nineteen indexed documents, 125 citations, and an h-index of six. These metrics indicate measurable academic visibility and engagement within the scientific community. His publications encompass medicinal chemistry, drug delivery technologies, cancer therapeutics, and pharmaceutical innovations.[1]

  • Affiliation with Dibrugarh University, India.
  • Research specialization in medicinal chemistry and pharmaceutical sciences.
  • Indexed publications in peer-reviewed journals.
  • Interdisciplinary collaboration involving drug discovery and therapeutic development.

Research Contributions

Jon Jyoti Sahariah has contributed to studies involving natural bioactive compounds, targeted cancer therapies, liposomal drug delivery systems, and pharmaceutical technologies. Several publications examine mechanisms for improving therapeutic efficacy while reducing adverse effects associated with conventional treatments. Research efforts in these domains contribute to ongoing developments in precision medicine and translational pharmaceutical science.[3]

  • Investigation of natural compounds with therapeutic potential.
  • Research on advanced liposomal drug delivery systems.
  • Contributions to targeted cancer therapy methodologies.
  • Participation in multidisciplinary biomedical research projects.

Publications

Selected scholarly works associated with Jon Jyoti Sahariah include publications addressing cancer chemotherapy, liposomal drug delivery, and medicinal chemistry innovations. Representative studies include highly cited articles focusing on natural bioactive compounds and targeted therapeutic approaches.[3]

  1. Cancer Chemotherapy via Natural Bioactive Compounds.
  2. Advancing Liposomal Doxorubicin for Targeted Cancer Therapy.
  3. Research involving pharmaceutical formulation and drug delivery technologies.
  4. Studies related to medicinal chemistry and therapeutic development.

Research Impact

Research impact can be assessed through publication output, citation frequency, collaborative scholarship, and relevance to scientific advancement. The citation record associated with Jon Jyoti Sahariah indicates that his work has been referenced by researchers in related fields, reflecting scholarly engagement and knowledge dissemination. Contributions to pharmaceutical sciences and medicinal chemistry support ongoing scientific dialogue regarding improved therapeutic interventions.[1]

Award Suitability

The Research Excellence Award recognizes researchers demonstrating meaningful scholarly contributions, scientific productivity, and academic influence. Based on available publication records, citation metrics, and participation in medicinal chemistry research, Jon Jyoti Sahariah exhibits characteristics consistent with the objectives of academic recognition programs. His work contributes to knowledge advancement in pharmaceutical and biomedical sciences while supporting innovation in therapeutic research.[1][4]

Conclusion

Jon Jyoti Sahariah has established a scholarly profile characterized by contributions to medicinal chemistry, drug delivery systems, and pharmaceutical sciences. Through peer-reviewed publications, citation impact, and collaborative scientific efforts, he has participated in research addressing significant healthcare and therapeutic challenges. His academic record supports consideration for professional recognition through the Research Excellence Award and reflects ongoing engagement with scientific advancement.[1]

References

  1. Scopus author details: Jon Jyoti Sahariah, Author ID 57225212218. Scopus. https://www.scopus.com/authid/detail.uri?authorId=57225212218
  2. Cancer chemotherapy via natural bioactive compounds. https://www.benthamdirect.com/content/journals/cddt/10.2174/1570163819666220331095744
  3. From bench to bedside: Advancing liposomal doxorubicin for targeted cancer therapy. https://www.sciencedirect.com/science/article/pii/S2666845925000601
  4. Revolutionizing patient care: 3D printing for customized medical devices and therapeutics. https://link.springer.com/article/10.1007/s44174-025-00324-2

Mr. Akash Vikal | Nanotechnology and Advanced Materials | Innovative Research Award

Mr. Akash Vikal | Nanotechnology and Advanced Materials | Innovative Research Award

IFTM University, Moradabad, India

Akash Vikal is an emerging pharmaceutical researcher specializing in pharmaceutics, nanomedicine, advanced drug delivery systems, and cancer therapeutics. His academic and research contributions primarily focus on the development of innovative formulation strategies designed to improve therapeutic efficacy, targeted delivery, and patient outcomes. Through extensive research in liposomal formulations, nanocarriers, gene delivery systems, and ocular therapeutics, he has established himself as a promising young contributor to modern pharmaceutical sciences.His research portfolio reflects interdisciplinary expertise integrating pharmaceutical technology, nanotechnology, oncology, ophthalmic therapeutics, and translational medicine. With numerous peer-reviewed publications, book chapters, and scientific presentations, he has actively contributed to advancing pharmaceutical innovation and drug delivery research.

Professional Profile 

Education

Akash Vikal completed a Bachelor of Pharmacy (B.Pharm.) from Shri Gopichand College of Pharmacy with strong academic performance. He further pursued a Master of Pharmacy (M.Pharm.) in Pharmaceutics from ISF College of Pharmacy, where he specialized in advanced pharmaceutical formulation and drug delivery systems. His postgraduate research focused on the “Development and Characterization of Ferulic Acid and Docetaxel Loaded Liposomes Against Breast Cancer” under the guidance of Balak Das Kurmi.

Professional Experience

During his academic journey, Akash Vikal gained industrial exposure through internship training at HIS Pharmaceuticals Pvt. Ltd., where he developed practical knowledge related to pharmaceutical manufacturing and formulation processes. He has also actively contributed to scientific communication and peer-review activities, including reviewing submissions for reputed journals such as Dovepress journals Clinical Ophthalmology and Eye and Brain. In addition, he delivered an academic webinar on scientific writing and publication strategies for researchers and healthcare professionals.

Research Interest

He has contributed extensively to pharmaceutical and biomedical research through numerous publications in reputed international journals. His research covers areas such as metal-organic frameworks in drug delivery, PROTAC-based cancer therapy, nanoparticle-mediated antimicrobial strategies, CRISPR-assisted nanotechnology, nanocarrier systems for ocular therapeutics, and phytoconstituent-based anticancer therapies. Several of his works have been published in recognized journals including Applied Materials Today, Drug Delivery and Translational Research, AAPS PharmSciTech, Current Pharmaceutical Design, and Experimental Eye Research.

Award and Honor

Akash Vikal has received recognition for his academic and scientific contributions through participation in national and international conferences, workshops, and faculty development programs. He earned a Certificate of Excellence in Peer Reviewing for his contribution to academic quality enhancement. His involvement in intellectual property awareness programs, pharmaceutical research conferences, and specialized training workshops reflects his commitment to continuous professional development and scientific advancement.

Conclusion

Mebratu Tafesse Teferi demonstrates strong potential for the Best Researcher Award. His substantial academic qualifications, leadership experience, and dedication to educational research are commendable. His publications reflect significant contributions to Ethiopian education and leadership studies, making him a valuable candidate for the award. To further enhance his candidacy, Mebratu could focus on broadening his research scope, fostering international collaborations, and increasing his publication reach in globally recognized journals.

Publications Top Noted

  • Next-generation gene editing strategies in cancer: Integrating CRISPR, PROTACs, and advanced molecular technologies
    Authors: Akash Vikal, Rashmi Maurya, Pradeep Kumar, Navneet Verma, Arun Kumar Mishra
    Year: 2026
  • Liposomal Paclitaxel in Breast Cancer Therapy: Advances, Clinical Insights, and Future Perspectives
    Authors: Akash Vikal, Rashmi Maurya, Navneet Verma, Arun Kumar Mishra
    Year: 2026
  • A Mini-Review on Unlocking Cognitive Enhancement: An Innovative Strategy for Optimal Brain Functions
    Authors: Akash Vikal, Rashmi Maurya, Brij Bihari Patel, Preeti Patel, Manish Kumar, Balak Das Kurmi
    Year: 2025
  • Andrographis paniculata in Fatty Liver Disease: Mechanisms, Nanocarrier Approaches, and Therapeutic Potential
    Authors: Akash Vikal, Rashmi Maurya, Preeti Patel, Balak Das Kurmi
    Year: 2025
  • Development of Mucopenetrating Pegylated Liposomes Functionalized with Sodium Taurocholate for Enhanced Oral Insulin Delivery
    Authors: Akash Vikal, Rashmi Maurya, Balak Das Kurmi, S. Jindal, R. K. Narang
    Year: 2025
  • From Resistance to Response: Metallic Nanoparticles as Game Changers in Triple Negative Breast Cancer Therapy
    Authors: Akash Vikal, Rashmi Maurya, Preeti Patel, R. K. Narang, Balak Das Kurmi
    Year: 2025
  • Lutein as a Liver Guardian: Insights into its Hepatoprotective Mechanisms, Bioavailability, and Emerging Therapeutic Roles
    Authors: Akash Vikal, Rashmi Maurya, Preeti Patel, Balak Das Kurmi
    Year: 2025
  • Nanoemulsion Technology in Oral Drug Delivery: A Path to Enhanced Solubility and Bioavailability
    Authors: Akash Vikal, Rashmi Maurya, Preeti Patel, Balak Das Kurmi
    Year: 2025
  • Role of dePEGylation in Vesicular Carriers-Mediated Stimuli-Responsive Drug Delivery to Tumors
    Authors: Akash Vikal, Rashmi Maurya, Abhinav Vashishat, Taqdir Singh, Satyam Khare, Preeti Patel, Balak Das Kurmi
    Year: 2025

 

Uma V | Materials Science | Women Researcher Award

Dr. Uma V | Materials Science | Women Researcher Award

Government Thirumagal Mill’s College | India

Dr. V. Uma is a dedicated physics educator and researcher specializing in advanced functional materials, particularly multiferroic nanomaterials and thin-film systems. She serves as a Guest Lecturer in the Department of Physics at Government Thirumagal Mills College, where she has handled extensive teaching responsibilities across UG and PG programs, guided numerous student projects, and delivered lectures in areas such as material science, microprocessors, electronics, nuclear physics, and numerical methods. Her academic background includes a Ph.D. in Physics focused on the synthesis and characterization of bismuth iron oxide nanomaterials, supported by an M.Phil. in Physical Sciences, M.Sc. in Physics, and a B.Ed. in Physical Science, along with qualification in the State Eligibility Test. Her research expertise covers nanomaterial synthesis using sol-gel, hydrothermal, microwave combustion, and thin-film deposition techniques, along with characterization skills in XRD, FTIR, UV, VSM, SEM, dielectric studies, and electrochemical analysis. She has published impactful research contributions with a citation count of 8, two indexed documents, and an h-index of 2, demonstrating emerging recognition within the scientific community. She has actively participated and presented in several national and international conferences in materials science. Her work reflects strong commitment toward innovative research, quality teaching, and the advancement of materials science applications.

Profile: Scopus

Featured Publications

Uma, V., & Seenuvasakumaran, P. (2023). Synthesis, structural, microstructural, optical, magnetic and dielectric properties of Nd-doped multiferroic Bismuth iron oxide. Results in Materials. https://doi.org/10.1016/j.rinma.2022.100359